A multicenter phase 1 trial of tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery in patients with brain metastases from HER-2–positive breast cancer (TUTOR). Article

Ahluwalia, Manmeet Singh, Ozair, Ahmad, Bardhan, Mainak et al. (2024). A multicenter phase 1 trial of tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery in patients with brain metastases from HER-2–positive breast cancer (TUTOR). . JOURNAL OF CLINICAL ONCOLOGY, 42(16_suppl), tps2089-tps2089. 10.1200/jco.2024.42.16_suppl.tps2089

cited authors

  • Ahluwalia, Manmeet Singh; Ozair, Ahmad; Bardhan, Mainak; Bellur, Shreyas S; Perche, Dilanis C; Starosciak, Amy K; Leon-Ariza, Daniel S; Khosla, Atulya Aman; Rubens, Muni; Odia, Yazmin; Mehta, Minesh P; Kotecha, Rupesh; McDermott, Michael W; Sandoval-Leon, Ana Cristina; Mahtani, Reshma L; Peereboom, David M

authors

publication date

  • June 1, 2024

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3202 Clinical Sciences
  • 3211 Oncology and Carcinogenesis
  • 6.1 Pharmaceuticals
  • Breast Cancer
  • Cancer
  • Clinical Research
  • Clinical Trials and Supportive Activities
  • Hematology
  • Neurosciences
  • Radiation Oncology
  • Women's Health

publisher

  • American Society of Clinical Oncology (ASCO)

start page

  • tps2089

end page

  • tps2089

volume

  • 42

issue

  • 16_suppl